source
- Pharma pours billions into bispecifics, ADCs and cell therapies despite limited clinical proofThe article notes that emerging drug formats such as bispecific antibodies, antibody‑drug conjugates and cell therapies have yet to demonstrate clear clinical success, yet pharmaceutical firms cont…
- FDA Issues Final Guidance on Prescription Drug Apps and SoftwareThe U.S. Food and Drug Administration today released final guidance establishing a clear framework for how drug companies can develop, distribute, and label apps used alongside their prescription m…fda press · 1h ago↗ source
- Roche signs up to $15 billion ADC partnership with China's Hansoh, paying $400 million upfront